[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 1997",
          "fs": "Sep 1997",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyeYUAQ"
          },
          "Id": "a0P2P000004pyeYUAQ",
          "Event_Date__c": "1997-09-01",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Formatted_Date__c": "Sep 1997",
          "Status_History__c": "a132P000000AomfQAC"
        },
        "change": null
      }
    ],
    "dateString": "Sep 1997",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 1997",
          "fs": "Sep 1997",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyeZUAQ"
          },
          "Id": "a0P2P000004pyeZUAQ",
          "Event_Date__c": "1997-09-15",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Sep 1997",
          "Status_History__c": "a132P000000AomgQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Low",
          "fs": "Low",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 1997",
          "fs": "Nov 1997",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Saturday 1 November 1997.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Saturday 1 November 1997.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyeaUAA"
          },
          "Id": "a0P2P000004pyeaUAA",
          "Event_Date__c": "1997-11-01",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Saturday 1 November 1997.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "Low",
          "Formatted_Date__c": "Nov 1997",
          "Status_History__c": "a132P000000AomoQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2013",
          "fs": "Sep 2013",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyedUAA"
          },
          "Id": "a0P2P000004pyedUAA",
          "Event_Date__c": "2013-09-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Sep 2013",
          "Status_History__c": "a132P000000CCCDQA4"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee recommended <b>not</b> listing another triptan on the Pharmaceutical Schedule</p><p style=\"text-align: justify;\">The Decision Criteria particularly relevant to this recommendation are: <i>(i) The health needs of all eligible people within New Zealand; (iii) The availability and suitability of existing medicines, therapeutic medical devices and related products and related things; (iv) The clinical benefits and risks of pharmaceuticals.</i> </p><p style=\"text-align: justify;\"><br></p><p><br></p>",
          "fs": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee recommended <b>not</b> listing another triptan on the Pharmaceutical Schedule</p><p style=\"text-align: justify;\">The Decision Criteria particularly relevant to this recommendation are: <i>(i) The health needs of all eligible people within New Zealand; (iii) The availability and suitability of existing medicines, therapeutic medical devices and related products and related things; (iv) The clinical benefits and risks of pharmaceuticals.</i> </p><p style=\"text-align: justify;\"><br></p><p><br></p>",
          "change": null
        },
        "Published_Discussion": {
          "s": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that in its meeting held on 24 July 2012 it had recommended that PHARMAC staff conduct a comparison of all available triptans (selective serotonin 5-HT1B/1D agonists), with particular focus on the rate of onset of action. </p><p style=\"text-align: justify;\">1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that rizatriptan (10mg orodispersible tablet) and sumatriptan (50 mg, 100mg tablets, and a 12mg injection) are currently listed in the Pharmaceutical Schedule.</p><p style=\"text-align: justify;\">1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the table provided by PHARMAC staff which provided a comprehensive overview of the pharmacokinetics (including the rate of action) of various triptans. (Drugs. 2000;60(6):1259-1287) </p><p style=\"text-align: justify;\">1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the triptans which have the most rapid onset of action includes the currently funded drugs, rizatriptan and sumatriptan.</p><p style=\"text-align: justify;\">1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a study by Johnson and Rappoport (Drugs 2010;70(12):1505-1616) which concluded that the most effective triptans are similar in effectiveness to sumatriptan 100mg and include rizatriptan 10mg, eletriptan 40mg, almotriptan 12.5mg and zolmatriptan 2.5mg.</p><p style=\"text-align: justify;\">1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that relatively few trials have compared the triptans head to head.</p><p style=\"text-align: justify;\">1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a systematic review on the efficacy and tolerability of marketed oral triptans in the acute treatment of migraine. (Pascual et al Headache. 2007;47(8):1152-68). The review reported that all marketed triptans provided significant relief and/or absence of pain at 2 hours, and relief at 1 hour when compared with placebo. </p><p style=\"text-align: justify;\">1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a review by Tfelt-Hansen et al (Drugs. 2000;60(6):1259-87). The review stated that sumatriptan has a low oral bioavailability and all the newer triptans have an improved oral bioavailability and for one, rizatriptan, the rate of absorption is faster. Members noted that the review stated that the half-lives of naratriptan, eletriptan and, in particular, frovatriptan are longer than that of sumatriptan but that the pharmacokinetic improvements of the newer triptans so far seem to have only resulted in minor differences in their efficacy in migraine. </p><p style=\"text-align: justify;\">1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that there are three triptans available in New Zealand: sumatriptan, rizatripan and the unfunded zolmatriptan.</p><p style=\"text-align: justify;\">1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the funded triptans are contraindicated in patients taking MAOI and also have a relative contraindication in patients taking SSRIs.</p><p style=\"text-align: justify;\">1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there may be benefits from the availability of other triptans, such as fovitriptan for the treatment of menstrual migraines.</p><p style=\"text-align: justify;\">1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>Members noted the prevalence of triptan overuse and consider that this was a public health issue. Members considered that the addition of further triptans to this therapeutic arena may have the potential to exacerbate this problem.</p><p style=\"text-align: justify;\">1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there may be a benefit in funding a triptan which could be administered nasally, such as nasal sumatriptan.</p><p><br></p>",
          "fs": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that in its meeting held on 24 July 2012 it had recommended that PHARMAC staff conduct a comparison of all available triptans (selective serotonin 5-HT1B/1D agonists), with particular focus on the rate of onset of action. </p><p style=\"text-align: justify;\">1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that rizatriptan (10mg orodispersible tablet) and sumatriptan (50 mg, 100mg tablets, and a 12mg injection) are currently listed in the Pharmaceutical Schedule.</p><p style=\"text-align: justify;\">1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the table provided by PHARMAC staff which provided a comprehensive overview of the pharmacokinetics (including the rate of action) of various triptans. (Drugs. 2000;60(6):1259-1287) </p><p style=\"text-align: justify;\">1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the triptans which have the most rapid onset of action includes the currently funded drugs, rizatriptan and sumatriptan.</p><p style=\"text-align: justify;\">1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a study by Johnson and Rappoport (Drugs 2010;70(12):1505-1616) which concluded that the most effective triptans are similar in effectiveness to sumatriptan 100mg and include rizatriptan 10mg, eletriptan 40mg, almotriptan 12.5mg and zolmatriptan 2.5mg.</p><p style=\"text-align: justify;\">1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that relatively few trials have compared the triptans head to head.</p><p style=\"text-align: justify;\">1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a systematic review on the efficacy and tolerability of marketed oral triptans in the acute treatment of migraine. (Pascual et al Headache. 2007;47(8):1152-68). The review reported that all marketed triptans provided significant relief and/or absence of pain at 2 hours, and relief at 1 hour when compared with placebo. </p><p style=\"text-align: justify;\">1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a review by Tfelt-Hansen et al (Drugs. 2000;60(6):1259-87). The review stated that sumatriptan has a low oral bioavailability and all the newer triptans have an improved oral bioavailability and for one, rizatriptan, the rate of absorption is faster. Members noted that the review stated that the half-lives of naratriptan, eletriptan and, in particular, frovatriptan are longer than that of sumatriptan but that the pharmacokinetic improvements of the newer triptans so far seem to have only resulted in minor differences in their efficacy in migraine. </p><p style=\"text-align: justify;\">1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that there are three triptans available in New Zealand: sumatriptan, rizatripan and the unfunded zolmatriptan.</p><p style=\"text-align: justify;\">1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the funded triptans are contraindicated in patients taking MAOI and also have a relative contraindication in patients taking SSRIs.</p><p style=\"text-align: justify;\">1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there may be benefits from the availability of other triptans, such as fovitriptan for the treatment of menstrual migraines.</p><p style=\"text-align: justify;\">1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>Members noted the prevalence of triptan overuse and consider that this was a public health issue. Members considered that the addition of further triptans to this therapeutic arena may have the potential to exacerbate this problem.</p><p style=\"text-align: justify;\">1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there may be a benefit in funding a triptan which could be administered nasally, such as nasal sumatriptan.</p><p><br></p>",
          "change": null
        },
        "Published_Application": {
          "s": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In its meeting held on 24 July 2012 the Neurological Subcommittee of the PTAC recommended that PHARMAC staff conduct a comparison of all available triptans (selective serotonin 5-HT1B/1D agonists), with particular focus on rate of onset of action.\u00a0</p><p><br></p>",
          "fs": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In its meeting held on 24 July 2012 the Neurological Subcommittee of the PTAC recommended that PHARMAC staff conduct a comparison of all available triptans (selective serotonin 5-HT1B/1D agonists), with particular focus on rate of onset of action.\u00a0</p><p><br></p>",
          "change": null
        },
        "PTAC_Comments": {
          "s": "<p>PTAC agreed with the recommendation made by the subcommittee at its February 2014 meeting</p>",
          "fs": "<p>PTAC agreed with the recommendation made by the subcommittee at its February 2014 meeting</p>",
          "change": null
        },
        "Outcome": {
          "s": "No Formal Recommendation",
          "fs": "No Formal Recommendation",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2013",
          "fs": "Sep 2013",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Neurological Subcommittee at meeting Friday 20 September 2013.",
          "fs": "Clinical advice received from Neurological Subcommittee at meeting Friday 20 September 2013.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyeeUAA"
          },
          "Id": "a0P2P000004pyeeUAA",
          "Event_Date__c": "2013-09-20",
          "Event_Description__c": "Clinical advice received from Neurological Subcommittee at meeting Friday 20 September 2013.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "No Formal Recommendation",
          "Formatted_Date__c": "Sep 2013",
          "Published_Recommendation__c": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee recommended <b>not</b> listing another triptan on the Pharmaceutical Schedule</p><p style=\"text-align: justify;\">The Decision Criteria particularly relevant to this recommendation are: <i>(i) The health needs of all eligible people within New Zealand; (iii) The availability and suitability of existing medicines, therapeutic medical devices and related products and related things; (iv) The clinical benefits and risks of pharmaceuticals.</i> </p><p style=\"text-align: justify;\"><br></p><p><br></p>",
          "Published_Application__c": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In its meeting held on 24 July 2012 the Neurological Subcommittee of the PTAC recommended that PHARMAC staff conduct a comparison of all available triptans (selective serotonin 5-HT1B/1D agonists), with particular focus on rate of onset of action.\u00a0</p><p><br></p>",
          "Published_Discussion__c": "<p style=\"text-align: justify;\">1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that in its meeting held on 24 July 2012 it had recommended that PHARMAC staff conduct a comparison of all available triptans (selective serotonin 5-HT1B/1D agonists), with particular focus on the rate of onset of action. </p><p style=\"text-align: justify;\">1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that rizatriptan (10mg orodispersible tablet) and sumatriptan (50 mg, 100mg tablets, and a 12mg injection) are currently listed in the Pharmaceutical Schedule.</p><p style=\"text-align: justify;\">1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the table provided by PHARMAC staff which provided a comprehensive overview of the pharmacokinetics (including the rate of action) of various triptans. (Drugs. 2000;60(6):1259-1287) </p><p style=\"text-align: justify;\">1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the triptans which have the most rapid onset of action includes the currently funded drugs, rizatriptan and sumatriptan.</p><p style=\"text-align: justify;\">1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a study by Johnson and Rappoport (Drugs 2010;70(12):1505-1616) which concluded that the most effective triptans are similar in effectiveness to sumatriptan 100mg and include rizatriptan 10mg, eletriptan 40mg, almotriptan 12.5mg and zolmatriptan 2.5mg.</p><p style=\"text-align: justify;\">1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that relatively few trials have compared the triptans head to head.</p><p style=\"text-align: justify;\">1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a systematic review on the efficacy and tolerability of marketed oral triptans in the acute treatment of migraine. (Pascual et al Headache. 2007;47(8):1152-68). The review reported that all marketed triptans provided significant relief and/or absence of pain at 2 hours, and relief at 1 hour when compared with placebo. </p><p style=\"text-align: justify;\">1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted a review by Tfelt-Hansen et al (Drugs. 2000;60(6):1259-87). The review stated that sumatriptan has a low oral bioavailability and all the newer triptans have an improved oral bioavailability and for one, rizatriptan, the rate of absorption is faster. Members noted that the review stated that the half-lives of naratriptan, eletriptan and, in particular, frovatriptan are longer than that of sumatriptan but that the pharmacokinetic improvements of the newer triptans so far seem to have only resulted in minor differences in their efficacy in migraine. </p><p style=\"text-align: justify;\">1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that there are three triptans available in New Zealand: sumatriptan, rizatripan and the unfunded zolmatriptan.</p><p style=\"text-align: justify;\">1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the funded triptans are contraindicated in patients taking MAOI and also have a relative contraindication in patients taking SSRIs.</p><p style=\"text-align: justify;\">1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there may be benefits from the availability of other triptans, such as fovitriptan for the treatment of menstrual migraines.</p><p style=\"text-align: justify;\">1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>Members noted the prevalence of triptan overuse and consider that this was a public health issue. Members considered that the addition of further triptans to this therapeutic arena may have the potential to exacerbate this problem.</p><p style=\"text-align: justify;\">1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that there may be a benefit in funding a triptan which could be administered nasally, such as nasal sumatriptan.</p><p><br></p>",
          "PTAC_Comments__c": "<p>PTAC agreed with the recommendation made by the subcommittee at its February 2014 meeting</p>",
          "Status_History__c": "a132P000000CCDFQA4"
        },
        "change": null
      }
    ],
    "dateString": "Sep 1997",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 1997",
          "fs": "Nov 1997",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyebUAA"
          },
          "Id": "a0P2P000004pyebUAA",
          "Event_Date__c": "1997-11-01",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Nov 1997",
          "Status_History__c": "a132P000000AomrQAC"
        },
        "change": null
      }
    ],
    "dateString": "Nov 1997",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 1998",
          "fs": "Dec 1998",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyecUAA"
          },
          "Id": "a0P2P000004pyecUAA",
          "Event_Date__c": "1998-12-31",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "Dec 1998",
          "Status_History__c": "a132P000000AonfQAC"
        },
        "change": null
      }
    ],
    "dateString": "Dec 1998",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<p>The consultation document can be found at: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-10-01-inactive-declines/</p>",
          "fs": "<p>The consultation document can be found at: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-10-01-inactive-declines/</p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Oct 2020",
          "fs": "Oct 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyefUAA"
          },
          "Id": "a0P2P000004pyefUAA",
          "Event_Date__c": "2020-10-01",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Links__c": "<p>The consultation document can be found at: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-10-01-inactive-declines/</p>",
          "Formatted_Date__c": "Oct 2020",
          "Status_History__c": "a132P000000ChNEQA0"
        },
        "change": null
      }
    ],
    "dateString": "Oct 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Oct 2020",
          "fs": "Oct 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyegUAA"
          },
          "Id": "a0P2P000004pyegUAA",
          "Event_Date__c": "2020-10-30",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Formatted_Date__c": "Oct 2020",
          "Status_History__c": "a132P000000ChNJQA0"
        },
        "change": null
      }
    ],
    "dateString": "Oct 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<p>The notification document can be found at: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-03-15-inactive-declines/</p>",
          "fs": "<p>The notification document can be found at: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-03-15-inactive-declines/</p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Mar 2021",
          "fs": "Mar 2021",
          "change": null
        },
        "Event_Description": {
          "s": "The funding application has been declined.",
          "fs": "The funding application has been declined.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004pyehUAA"
          },
          "Id": "a0P2P000004pyehUAA",
          "Event_Date__c": "2021-03-15",
          "Event_Description__c": "The funding application has been declined.",
          "Stage__c": "Decision",
          "Links__c": "<p>The notification document can be found at: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-03-15-inactive-declines/</p>",
          "Formatted_Date__c": "Mar 2021",
          "Status_History__c": "a132P000000ChNOQA0"
        },
        "change": null
      }
    ],
    "dateString": "Mar 2021",
    "collapsed": false,
    "checked": true
  }
]